CEU 2015 Session Recordings

The scientific content of the CEU 2015 Session Recordings was developed by the Clinical Endocrinology Update Steering Committee, independent of and prior to the solicitation of grant support. As a provider of independent and continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous.

While the CEU 2015 Session Recordings do not offer AMA PRA Category 1 Credits™, its content was developed, in accordance with the ACCME's Essential Areas and Elements, including the Standards for Commercial Support. The commercial supporters of this meeting have no influence over topics or speakers. Educational grants support the production costs of the overall activity and are not used to compensate speakers in supported sessions.

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, internists, healthcare professionals who treat endocrine disorders, and others seeking an update in recent developments in the treatment of endocrine disorders.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Discuss state-of-the-art research in endocrinology
  • Demonstrate updated knowledge of the diagnosis and treatment of diabetes, lipid, osteoporosis, pituitary, adrenal, thyroid, and reproductive endocrine disorders
  • Employ enhanced skills and practice management techniques to improve patient care

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Systems-based Practice
Topic Area: 
Adrenal/HPA Axis
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Quality Improvement and Healthcare Delivery
General Endocrinology
Hormone Abuse
Growth Disorders
Health Disparities
Hormones and Cancer
Men’s Health
Neuroendocrinology and Pituitary
Pediatric Endocrinology
Thyroid/HPT Axis
Women’s Health
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Course opens: 
Course expires: 

Disclosure Policy

The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

John P. Bilezikian, MD: Advisory Board, Radius Pharmaceuticals; Advisory Board and Consultant, Amgen, Eli Lilly & Co., Merck & Co., Glaxo-Smith-Kline; Advisory Board, Consultant, and Research Funding, NPS Pharmaceuticals; Consultant, Bristol Myers Squibb, Johnson & Johnson

Beverly M. K. Biller, MD: Consultant, HRA Pharmaceuticals; Consultant and Research Funding, Cortendo, Novartis Pharmaceuticals

Adi Cohen, MD, MHS: Research Funding, Amgen, Eli Lilly & Co.

Anne C. Goldberg, MD: Advisory Board Member, Consultant, and Research Funding, Regeneron, Sanofi-Aventis; Consultant, AstraZeneca, uniQuire; Editor, Merck & Co., Inc. Manual of Diagnosis and Therapy; Research Funding, Amarin Pharma, Inc., Amgen, Genzyme, Glaxo-Smith-Kline, Isis Pharmaceuticals, Merck & Co., Inc., Pfizer

Ronald B. Goldberg, MD: Consultant, Sanofi-Aventis

David S. Goldfarb, MD: Consultant, AstraZeneca, CymaBay Therapeutics, Pfizer, Retrophin; Owner and Patent Holder: The Ravine Group

Bryan R. Haugen, MD: Research Funding, Genzyme; Speaker, Veracyte

Jennifer L. Larsen, MD: Consultant, American Board of Internal Medicine, Endocrine Reviews Editorial Board; Consultant and Advisory Board Member, Dance Pharmaceuticals

Michael Mannstadt, MD: Ad Hoc Consultant, Amgen, Chugai; Advisory Board and Site Investigator, NPS Pharmaceuticals

Shlomo K. Melmed, MD: Speaker, Novartis Pharmaceuticals; Consultant, Chiasma, Isis Pharmaceuticals, Ipsen Pharmaceuticals; Research Funding, Pfizer

Douglas S. Ross, MS, MD: Clinical Advisor, Eisai

Guillermo E. Umpierrez, MD: Consultant, Novo Nordisk; Consultant and Investigator, Boehringer Ingelheim, Merck & Co.

Joseph G. Verbalis, MD: Consultant, Ferring Pharmaceuticals, Otsuka Pharmaceuticals

Carol H. Wysham, MD: Consultant and Speaker, AstraZeneca, Boerhinger Ingelheim, Eli Lilly & Co., Janssen Pharmaceuticals, Sanofi-Aventis


The following faculty reported no relevant financial relationships: Bradley D. Anawalt, MD; Linda A. Barbour, MD, MSPH; Shehzad S. Basaria, MD, MBBS; Richard S. Bockman, MD; David S. Cooper, MD; Marc Cornier, MD; James W. Findling, MD; Stephanie A. Fish, MD; Jose C. Florez, MD, PhD; Jacqueline Jonklaas, MD, PhD, MPH;  Laurence Katznelson, MD; Susan J. Mandel, MD, MPH; Jennifer B. Marks, MD; Kathryn A. Martin, MD; Connie B. Newman, MD; Kwame Osei, MD; Anand Vaidya, MD, MMSc; Margaret E. Wierman, MD; William F. Young, Jr., MD, MSc

The CEU Steering Committee members who planned and/or reviewed content for this activity reported the following relevant financial relationship(s):

Carlos A. Aguilar Salinas, MD: Research Funding, Sanofi-Aventis

George A. Bray, MD: Advisor, Medifast, Inc.; Advisory Board Member, Herbalife Nutrition Institute; Consultant, Novo Nordisk; Speaker, Takeda

Kathleen M. Dungan, MD, MPH: Advisory Board Member, Eli Lilly & Co.; Consultant and Research Funding, Glaxo-Smith-Kline; Research Funding, AstraZeneca, Grifols, Merck & Co., Regeneron, Sanofi

Maria Fleseriu, MD: Consultant, Xoma; Consultant and Research Funding, Novartis Pharmaceuticals; Research Funding, Cortendo, Opko, Pfizer

Whitney S. Goldner, MD: Consultant, Bayer; Council Member, Association of Program Directors in Endocrinology and Metabolism; Trainee Advancement Committee Chair, American Thyroid Association; Research Funding, AstraZeneca, Eisai

Susan A. Sherman, MD: Stock, BMS, HCA, ARCA Pharma; Spouse: Speaker, AstraZeneca

Hirotaka Shibata, MD, PhD: Committee Member, Japanese Society of Hypertension 2014 Guideline; Speaker, Astellas, Daiichi Sankyo, Dainippon-Sumitomo Pharmaceuticals, MSD, Pfizer, Inc. Japan, Takeda; Vice Director, Japan Endocrine Society Primary Aldosteronism Guideline


The following CEU Steering Committee members who planned and/or reviewed content for this activity reported no relevant financial relationships: Carolyn B. Becker, MD; Ann E. Kearns, MD, PhD;   J. Ariel Sánchez, MD, PhD; Janet A. Schlechte, MS, MD; Nalini S. Shah, DM; Jennifer A. Sipos, MD; Priyathama Vellanki, MD 

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.